REGENERON BREAKS OUT: IS $1,147 THE NEXT MAJOR TARGET?Regeneron Pharmaceuticals, Inc.BATS:REGNOmorfus✅ Regeneron Pharmaceuticals #REGN is one of the leading U.S. biotechnology companies, focused on developing and commercializing treatments in ophthalmology, immunology, oncology, and rare diseases. Its key products include Dupixent, EYLEA HD, and Libtayo. 📊 FUNDAMENTAL ANALYSIS 🟢 In Q2 2026, Regeneron’s revenue increased 17% year-over-year to $4.29 billion. 🟢 Global sales of Dupixent reached a new record, rising 38% to $6.0 billion. The drug remains one of the company’s key growth drivers. 🟢 U.S. sales of EYLEA HD increased 52% to a record $596 million. Quarterly EYLEA HD sales exceeded those of traditional EYLEA for the first time, confirming a successful transition toward the newer-generation treatment. 🟢 Sales of oncology drug Libtayo increased 30% to a record $489 million. 🟢 Regeneron maintains a strong development pipeline with approximately 50 clinical programs, creating additional potential growth drivers for the coming years. 🟢 Regulatory applications for cemdisiran for generalized myasthenia gravis are under review, potentially expanding the company’s future product portfolio. 🔴 One of the main fundamental risks remains declining sales of traditional EYLEA. Combined U.S. sales of EYLEA HD and EYLEA declined 12% year-over-year amid increasing competition and the transition toward EYLEA HD. 🔴 The biotechnology sector remains highly sensitive to clinical trial results, regulatory decisions, competition, and patent-related risks. 🛠 TECHNICAL ANALYSIS 📈 LONG ▪️ The analysis is based on the weekly timeframe. ▪️ After a prolonged correction, the stock formed a major bullish reversal structure — a W pattern, also known as a Double Bottom. ▪️ Price has broken above the neckline resistance of the W pattern around $800–815, providing an important technical signal that the medium-term bearish structure may have ended. ▪️ The stock is now trading above the breakout zone. Holding this area as new support would significantly strengthen the bullish continuation scenario. ▪️ Price has also moved above both the 50 EMA and the 200 EMA on the weekly chart, adding further confirmation to the medium-term bullish setup. ▪️ The 50 EMA is beginning to turn higher, while price is once again trading above both major moving averages. ▪️ A bullish divergence has formed on RSI: while price retested its lows, the oscillator formed a higher low, signaling weakening bearish momentum. ▪️ RSI has recovered above the neutral zone and continues to move higher without reaching extreme overbought levels. ▪️ OsMA has moved into positive territory, while the expanding positive histogram confirms strengthening bullish momentum. ▪️ The combination of the W-pattern breakout, recovery above the major EMAs, and bullish RSI divergence creates a strong medium-term reversal setup. ↗️ TRADE 🎯 Target 1 — $936.33 🎯 Target 2 — $1,147.56 📊 Upside potential to Target 1 — approximately 13%. 📊 Upside potential to Target 2 — approximately 39%. As long as price holds above the $800–815 breakout zone, the primary scenario remains a continuation of the bullish move toward the indicated targets. A return below the neckline of the W pattern and sustained trading back underneath it would be the first warning sign of a potential false breakout and would require reassessing the setup. 💼 Portfolio: #active_management ⚠️ The ideas published here are not investment recommendations. They represent only the author’s personal opinion.